Hosseini Seyed Kianoosh, Tahvildari Maryam, Alemzadeh Ansari Mohammad Javad, Nakhjavani Manouchehr, Esteghamati Alireza, Lotfi Tokaldany Masoumeh
Department of Cardiology, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, IR Iran.
Tehran University of Medical Sciences, Tehran, IR Iran.
Iran Red Crescent Med J. 2013 Jun;15(6):467-72. doi: 10.5812/ircmj.3370. Epub 2013 Jun 5.
High cholesterol levels have long been considered an independent risk factor for cardiovascular disease (CVD).
Controlling risk factors such as dyslipidemia in patients with coronary artery disease is necessary. We aimed to evaluate the success rate of lipid control, during 9 months follow-up after percutaneous coronary intervention (PCI).
A total of 195 patients (67.7% men, mean age = 57.8 ± 9.4 years) who underwent PCI in Tehran Heart Center were included. Serum lipid profiles were measured in all the patients before PCI and at 9-month follow-up. Dyslipidemia was defined as serum levels of LDL-C ≥ 100 or TG ≥ 150 or TC ≥ 200 or HDL-C ≤ 40 mg/dl in the men and ≤ 50 mg/dl or less in the women, or non-HDL-C ≥ 130 mg/dl with or without the consumption of lipid-lowering agents. During follow up, all patients were given atorvastatin 20-40 mg/day.
Overall, 26.2% had diabetes mellitus, 42.6% had hypertension, and 34.9% were smokers. Dyslipidemia was more common in the women. At 9-month follow-up, there was no significant changes in terms of the prevalence of high HDL-C or low TG in patients; however, a significant increase was seen in the prevalence low TC in patients (63.6% vs. 80.5%; p value < 0.001), LDL-C (47.2% vs. 65.6%; p value < 0.001), and non-HDL-C (40.0% vs. 63.1%; p value < 0.001).
Although by current treatments, the prevalence of patients with low TC, LDL-C and non-HDL-C has significantly increased; dyslipidemia persisted in a considerable proportion of patients. These results necessitate further investigations into the relationship between high serum lipids and long-term outcome of patients after PCI as well as further evaluations of the dyslipidemia treatment strategies.
长期以来,高胆固醇水平一直被视为心血管疾病(CVD)的独立危险因素。
控制冠状动脉疾病患者的血脂异常等危险因素很有必要。我们旨在评估经皮冠状动脉介入治疗(PCI)后9个月随访期间的血脂控制成功率。
纳入德黑兰心脏中心195例接受PCI治疗的患者(男性占67.7%,平均年龄=57.8±9.4岁)。在所有患者PCI术前及9个月随访时测量血脂谱。血脂异常定义为男性血清低密度脂蛋白胆固醇(LDL-C)≥100或甘油三酯(TG)≥150或总胆固醇(TC)≥200或高密度脂蛋白胆固醇(HDL-C)≤40mg/dl,女性≤50mg/dl或更低,或非HDL-C≥130mg/dl,无论是否服用降脂药物。随访期间,所有患者均给予阿托伐他汀20 - 40mg/天。
总体而言,26.2%的患者患有糖尿病,42.6%患有高血压,34.9%为吸烟者。血脂异常在女性中更为常见。在9个月随访时,患者中高HDL-C或低TG的患病率无显著变化;然而,患者中低TC(63.6%对80.5%;p值<0.001)、LDL-C(47.2%对65.6%;p值<0.001)和非HDL-C(40.0%对63.1%;p值<0.001)的患病率显著增加。
尽管通过当前治疗,低TC、LDL-C和非HDL-C患者的患病率显著增加;但相当一部分患者仍存在血脂异常。这些结果需要进一步研究高血清脂质与PCI术后患者长期预后之间的关系,以及进一步评估血脂异常的治疗策略。